WTX-330

DRUG2 trials

Sponsors

Werewolf Therapeutics, Inc.

Conditions

Advanced or Metastatic Solid TumorsNon-Hodgkin Lymphoma

Phase 1

WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma

CompletedNCT05678998

Werewolf Therapeutics, Inc.Advanced or Metastatic Solid Tumors, Non-Hodgkin Lymphoma

Start: 2022-12-06End: 2025-02-05Updated: 2026-01-06

A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Lymphoma

Active, not recruitingNCT06939283

Werewolf Therapeutics, Inc.Advanced or Metastatic Solid Tumors, Non-Hodgkin Lymphoma

Start: 2025-05-07End: 2028-08-01Target: 100Updated: 2026-02-10

Related Papers

Abstract A074: Discovery of WTX-330, a clinical stage conditionally activated IL-12 INDUKINETM therapeutic with potent antitumor activity in murine syngeneic tumor models resistant to checkpoint blockade

Molecular Cancer Therapeutics2023-12-01

1058 Optimal antitumor immunity triggered by WTX-124, a clinical stage conditionally activated INDUKINE<sup>TM</sup> molecule that releases fully potent IL-2 in the tumor microenvironment

Regular and Young Investigator Award Abstracts2023-10-31

Abstract CT254: Trial in progress: a first-in-human, phase 1, multicenter dose escalation and dose expansion study of WTX-330 in adult patients with advanced or metastatic solid tumors or non-Hodgkin lymphoma

Cancer Research2023-04-14